Walgreen (NYSE: WAG) shares are looking healthy Tuesday morning following the company's second-quarter 2012 results which showed a beat on the top and bottom lines amid a tough cold/flu season.

Revenue for the retail pharma giant moved 0.8 percent from $18.50 billion in the same period last year to $18.65 billion. Comps were down 1.5 percent, surprising when Walgreen reported front-end comps rose 2.1 percent, traffic was up 0.7 percent in comparable stores, and basket size jumped 1.4 percent.

Net earnings fell 7.6 percent to $683 million, or 78 cents per diluted share.

The Street expected revs of $18.53 billion and EPS of 77 cents.

Flu shots totaled 5.5 million, versus 6.2 million in the same period last year.

Comparable-store prescription sales dipped 3.9 percent, while overall prescription sales dropped 1.7 percent.

Walgreen said it had 700,000 new Prescription Savings Club sign-ups in January alone, following the exit of its partnership with Express Scripts (Nasdaq: ESRX).

***And, yes, we inquired: there is no special handshake or secret decoder ring given to you after signing-up to be part of the PSC.

Shares are up 2 percent Tuesday.

Corporate News Earnings